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The aim of this paper was to provide an overview of the current knowledge and understanding of the potential
beneficial physiological effects of glucosamine (GlcN) on joint health. The objective was to reach a consensus on
four critical questions and to provide recommendations for future research priorities. To this end, nine scientists
from Europe and the United States were selected according to their expertise in this particular field and were
invited to participate in the Hohenheim conference held in August 2011. Each expert was asked to address a
question that had previously been posed by the chairman of the conference. Based on a systematic review of the
literature and the collection of recent data, the experts documented the effects of GlcN on cartilage ageing,
metabolic/kinetic and maintenance of joint health as well as reduction of risk of OA development. After extensive
debate and discussion the expert panel addressed each question and a general consensus statement was
developed, agreeing on the current state-of-the-art and future areas for basic and clinical studies. This paper
summarizes the available evidence for beneficial effects of GlcN on joint health and proposes new insight into the
design of future clinical trials aimed at identifying beneficial physiological effect of GlcN on joint tissues.
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Glucosamine (GlcN) may be a suitable intervention
for osteoarthritis (OA) and, indeed, is already self-
administered by millions of individuals without any ap-
parent deleterious side-effects. GlcN is and ubiquitous
amino sugar that is believed to play a key role in cartil-
age formation and repair. It is a naturally occurring sub-
stance in the body and is essential for the normal
growth and repair of connective tissues such as articular
cartilage in synovial joints. GlcN is one of the major
constituents of the extracellular matrix (ECM) of cartil-
age and a building block for proteoglycan synthesis. It
exists in several forms, GlcN sulfate (GlcN.S) and GlcN
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reproduction in any medium, provided the orstudied. GlcN.S has been reported to be efficient on
knee OA symptoms [1-5].
In this paper, our goal was to explore new avenues
concerning the use of GlcN, especially in terms of bene-
ficial and disease preventing physiological effects, not-
ably with respect to OA development. To address this
aim, eight experts from six European countries and one
expert from the United States were selected and invited
according to their expertise in the context of this par-
ticular field, to the Hohenheim conference, which was
held in August 2011. Each expert was asked to address a
question that has been previously posed by the chairman
of the conference. Responses were based on review of
the published literature and the collection of the most
relevant papers and recent relevant data. Following ex-
tensive debate and discussion, a general consensus was
reached in relation to each question and new strategies
were proposed and discussed for basic and clinical fu-
ture works (Tables 1 and 2).al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of the experts group consensus
1 At the present time there is no evidence that glucosamine
modulates ageing phenotype and no studies have been performed
on the effects of glucosamine on aged cartilage.
2 New and more focused studies are clearly needed to determine if
GlcN can affect oxidative stress, mitochondrial function, autophagy
and responsiveness to cytokines and growth factors.
3 Chondrocytes have the capacity to biosynthesize glucosamine from
glucose in health and disease. There is no evidence that chondrocyte
glucosamine requirement is modified with age or pathological
situation.
4 The endogenous level of glucosamine is comprised between 1μM
and 2μM, and reach to 10 μM after oral administration of a
therapeutic dose (1500 mg);
5 There is no information about the optimal dose use and no
information of the interference of diet, age and other gastrointestinal
comorbidities or association with other nutraceuticals most
particularly with chondroitin sulfate on the GlcN phamarcokinetic
profile.
6 Glucosamine might contribute to the maintenance of healthy joints,
but this should be confirmed in clinical trials designed to investigate
its effects on healthy subjects with high risk of osteoarthritis and
using parameters, which establish the link between consumption of
glucosamine and maintenance of joints (e.g. biochemical markers
and/or MRI).
7 In vitro and ex vivo studies on normal and OA chondrocytes
demonstrated stimulating effect of GlcN with supra-pharmacological
concentrations on the synthesis of cartilage matrix components and
inhibiting potencies on pro-catabolic and pro-inflammatory factors.
8 Prophylactic evidence has been shown in some animal models, but
not in human.
9 More research is necessary to explore possible beneficial effects of
GlcN in healthy subjects or on risk factors of OA.
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evidence on the beneficial effects of GlcN on the joint
health. Based on a research of the literature performed
on PubMed, the experts attempted to document the ef-
fects of GlcN on cartilage ageing and maintenance of
joint health, two key points for the substantiation of
health claims. They have also provided some suggestions
for the design of future clinical trials in order to identify
beneficial physiological effects of GlcN on joint tissues.
What is the main impact of cartilage ageing? is GlcN
effective against cartilage ageing?
Ageing is a major contributor to musculoskeletal impair-
ment, the degeneration of joint tissues and the develop-
ment of OA [6,7]. Age-related changes in articular
cartilage contribute to the development and progression
of OA. Although the degeneration of articular cartilage is
not simply the result of ageing and mechanical wear, it
nevertheless modifies the articular joint tissues and syn-
ovial fluid [6,8]. Although older age is the greatest risk fac-
tor for OA, OA is not an inevitable consequence of
growing old [9]. The mechanisms for the link between
ageing and OA are incompletely understood. Cell stress
and oxidative damage contribute to chronic inflammationthat promotes age-related diseases. Ageing chondrocytes
express a so-called “senescent” secretory phenotype, which
has some common characteristics with chondrocyte
phenotype in OA, especially in relation to the production
and secretion of pro-inflammatory cytokines, chemokines,
and proteases [10].
One may question if the oral intake of GlcN could
interfere with chondrocyte senescence mechanisms. At
this time, it remains difficult to answer the question “is
GlcN effective against cartilage ageing or is this com-
pound effective on the ageing phenotype”. Indeed there
is no published evidence to suggest that GlcN is effective
against cartilage or any other connective tissues ageing.
Although there is some evidence to suggest that glucose
can accelerate in vitro cell senescence, there is no evi-
dence that GLcN can act in one way or another on it.
However, considerable evidence for indirect effects of
GlcN on ageing has been obtained. A recent proteomic
study [11] has shown that GlcN.S alters the expression
of proteins involved in signal transduction pathways,
redox and stress responses, and protein synthesis and
folding processes in human chondrocytes. Interestingly,
GlcN affects mainly energy production and metabolic
pathways. However, there is no “mechanistic” data
linking GlcN.S to the reduction of oxidative stress in
in vitro or animal studies.
Another study suggests that alpha-tocopherol, ascorbic
acid, selenium, combined GlcN.S and chondroitin exert
antioxidant effects on cultured chondrocytes [12]. How-
ever, this study used combination products. It is there-
fore difficult to determine whether GLcN by itself has
any direct and specific effects on oxidative stress.
Finally, a study investigated the effects of GlcN.S on
heme oxygenase (HO-1), p22 (Phox) (a subunit of
NADPH complex) and inducible nitric oxide synthase
(iNOS) expression by primary human chondrocytes
in vitro [13]. HO-1 gene expression was up-regulated by
10 mmol/l GlcN.S (24 h). Expression of the p22 (Phox)
gene was down-regulated by 10 mmol/l GlcN.S (48 h
treatment); the HO-1 gene was down-regulated by IL-1β
and 10 mmol/l GlcN.S appeared to restore the expres-
sion levels to baseline values.
It has recently been described that OA was associated
with an alteration in the O-N-actetyl-glycosaminylation
(O-GlcNAc) of proteins in the cartilage of patients [14].
Since the discovery of this protein modification by
Torres and Hart [15], O-GlcNAc signalling has been im-
plicated in a diverse array of physiological and patho-
logical functions [16]. Furthermore, there is a growing
recognition that global protein O-GlcNAc alterations are
involved in the pathophysiology of chronic- and age-
related diseases, such as diabetes, cardiac hypertrophy
and failure, immunological disorders, cardiovascular
disease, neurodegeneration and cancer [17,18]. In this
Table 2 Consensus and research recommendations for each question addressed
Question 1. What is the main impact of cartilage ageing? Is GlcN effective against cartilage ageing?
Consensus Research recommendations
Although older age is the greatest risk factor for OA, OA is not an
inevitable consequence of growing old.
To investigate GlcN on the following parameters:
• Telomere erosion
1. Chondrocytes have the capacity to biosynthesize GlcN from glucose in
health and disease. There is no evidence that chondrocyte GlcN
requirement is modified with age or pathological situation.
• Mitochondrial dysfunction
• Reactive oxygen species (ROS) and antioxidants production
2. To study the influence of ageing on the synthesis of GlcN by
chondrocytes in in vitro and spontaneous models of OA in animal is
recommended.
• Responsiveness to anabolic growth factors
3. Study of the production of GlcN by chondrocytes at different stages of
OA development in animal models should be performed.
• Autophagy
4. The senescence-associated secretory phenotype of articular
chondrocytes should be better characterized to differentiate ageing and
OA affected cartilage.
• Apoptosis
5. At the present time there is no evidence that GlcN modulates this
phenotype and no studies have been performed on the effects of GlcN
on aged cartilage. New and more focused studies are clearly needed to
determine if GlcN can affect oxidative stress, mitochondrial function,
autophagy and responsiveness to cytokines and growth factors.
• The expression of transcription factors associated with longevity (i.e.
SirT1 and FoxO)
6. There is some in vitro evidence that GlcN modulate glucose
metabolism is chondrocytes.
• The accumulation Advanced Glycation End products in ECM.
7. There is some evidence on systemic effect of GlcN through reduction
of inflammatory marker and anabolic effects on cartilage.
Question 2. How does the metabolic kinetic look like? What about the Cmax levels?
Consensus Research recommendations
1. Heterogeneous level of endogenous level of GlcN is comprised
between 1μM and 2μM
• To study the influence of various diets enriched in GlcN and ageing on
the endogenous level of GlcN
2. Translation of animal models concerning the basal level must been
done with caution because there are species differences in GlcN in
absorption and bioavailability.
• To better quantify the resting plasma levels of GlcN with future
developments in MS-technologies and bioanalytical techniques that
should contribute to the standardization of assays used to detect.
3. There is no information on the interference of diet, age and other
gastrointestinal comorbidities on the GlcN phamarcokinetic profile.
• To study higher doses of GlcN in human OA to look for beneficial
mechanisms of action of GlcN.S in experimental models
• To perform more pharmacokinetic and pharmacodynamic studies in
human as well as in animals
• To consider the formulation and complexation of the preparations in
future in vitro studies on GlcN
• To take into account the serum and synovium levels from clinical trials
(physiological effects found around serum levels of 10μM) to determine
the in vitro concentration used in future studies should take into account
• To better investigate the distribution of GlcN in the different joint
tissues
Question 3. How can GlcN contribute to cartilage maintenance in healthy subjects, and how can it be demonstrated?
Consensus Research recommendations
1. GlcN might contribute to the maintenance of joint health in OA
patients, but this should be demonstrated in clinical trials designed to
investigate its effect on healthy subjects with high risk of OA and
evaluating parameters which can establish the link between consumption
of GlcN and the maintenance of joints (e.g. biochemical markers and/or
MRI). This statement is based on the following observations:
• To investigate the effect of GlcN in the maintenance of healthy subjects.
This should be done as recommended in the framework of OARSI, in
young subjects with high risk factors of OA
• To investigate the effects of GlcN on a panel of functional imaging and
biochemical markers investigating joint tissue metabolism.
- In vitro and ex vivo studies on normal and OA chondrocytes
demonstrated stimulating effect of GlcN with supra-pharmacological
concentrations on the synthesis of cartilage matrix components and
inhibiting potencies on pro-catabolic and pro-inflammatory factors.
- Prophylactic evidence has been shown in some animal models.
- Up-to-date, there is no convincing data demonstrating the potential
benefit of GlcN in healthy subjects.
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Table 2 Consensus and research recommendations for each question addressed (Continued)
Question 4. Can GlcN reduce the risk of OA development?
Consensus Research recommendations
1. No data on modulating risk factors of OA. • To search the influence of GlcN on metabolic (e.g. adipokine secretions,
systemic inflammation) and structural risk factors (e.g.; osteophytes, bone
marrow lesions)2. Some animal and cases report in human suggest that chronic use of
GLcN in diabetes or “pre-diabetes” individuals might lead to insulin
resistance. However the level of proofs is not sufficient and we lack long
term studies of GlcN use for individuals with diabetes or pre diabetes.
Based on the available evidence, no specific recommendation for
controlling glycemia in patients taking GlcN could be addressed
• To identify surrogate marker for risk factors investigation (e.g. multiplex
biological test including markers of inflammation, glucose, fat tissue,
bone and cartilage metabolism or aggregate score integrating biological,
imaging and clinical)
• To design clinical trials on well-defined subgroups with a specific risk
profile (metabolic syndrome, etc.) to demonstrate beneficial effects of
GlcN on risk factors or risk profile.
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through the hexosamine pathway modifying the amount
of O-GlcNAc acylated proteins, and thus acting as a pro-
tective agent against cell stress and promoting cell survival
[19]. Preliminary data from Herrero Beaumont’s labora-
tory show that glucosamine treatment could diminish OA
damage in parallel with a diminution in O-GlcNAc modi-
fied proteins (Largo, unpublished data).
Another indirect effect of GlcN on ageing could happen
through its effect on inflammation. A number of recent
publications described anti-inflammatory effects of high
dose of GlcN in rheumatoid arthritis models [20,21].
These findings are underlined by studies with physio-
logical concentrations of GlcN.S where increased levels of
mRNA and aggrecan core protein and a decrease of the
production of MMP-3 in human OA chondrocytes were
investigated [22]. The study of Byron et al. using equine
chondrocytes and synovial cells found that GlcN.H de-
creased the IL-1-stimulated production of prostaglandins
(PGEs) in both cell types [23].
Do GLcN interfere with glucose metabolism in
chondrocytes?
A key question is “is GlcN capable to interfere with glu-
cose metabolism of chondrocytes?”. Chondrocytes are
highly glycolytic and glucose is an important metabolic
fuel for fully differentiated chondrocytes both during
postnatal development and in adult articular cartilage
[24]. Glucose is also a common structural precursor for
the synthesis of extracellular matrix glycosaminoglycans
(GAGs) [24]. In addition, chondrocytes express the insu-
lin receptor and are very sensitive to extracellular and
intracellular glucose levels [25]. Healthy chondrocytes
have a negative feedback loop for controlling the uptake
of glucose by modulating the expression of glucose
transporter-1 (GLUT-1), depending on extracellular
glucose levels. Therefore, if extracellular glucose in-
creases, chondrocytes induce the degradation of GLUT-
1. However in OA chondrocytes, this feedback appears
to be disturbed. Hence, under high glucose, GLUT-1transporters cannot adequately be down regulated and
intracellular glucose accumulation occurs with subse-
quent deleterious effects [26,27]. This is an extremely
interesting phenomenon that might have major reper-
cussions for the aged population where undetected
diabetes (i.e. subclinical, mild) and early OA occur
frequently together. This fact might explain a potential
mechanism of action of GlcN that shares the GLUT
transporter system with glucose. Thus high concentra-
tions of GlcN.S and GlcN.H might potentially act as a
competitive inhibitor for glucose uptake [28] and protect
chondrocytes against high glucose. Intracellular competi-
tion may also occur at substrate level since glucose and
GlcN are both phosphorylated by the same enzyme, glu-
cokinase (hexokinase). However, in turn, phosphorylated
GlcN is an allosteric inhibitor of glucokinase. The conse-
quence of this is a negative feedback loop that blocks
glycolysis [29,30]. Nevertheless, different forms of GlcN
might act somehow differently since N-acetyl-GlcN is
phosphorylated by a different enzyme preventing the
intracellular competition with glucose [31]. It might be
possible that GlcN can achieve both, activating insulin
resistance and/or blocking glycolysis, depending on cell
phenotype, disease status and specific form of the amino
sugar.
How does the metabolic kinetic look like? What about the
Cmax levels?
GlcN is highly active when added to cell cultures or used
in animal models at high concentrations [32]. While sev-
eral studies have published information about the mech-
anism of action of GlcN, its pharmacokinetics has only
been recently described. The lack of sensitive analytical
methods capable of detecting the compound in biological
fluids has been the primary limitation of pharmacokinetic
studies. In addition, other major difficulties associated
with the quantitative determination of GlcN in biological
samples are low GlcN levels and the presence of many
structurally related sugar molecules that can interfere with
its analysis [33,34].
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profile of GlcN, after three oral doses (once daily, con-
secutive administration) of 1500 mg crystalline GlcN.S
in healthy volunteers [35]. GlcN is bioavailable from or-
ally administered crystalline GlcN.S with maximum
plasma concentrations up to 100-fold higher than en-
dogenous levels, in the 10 μM range after approximately
3 h post ingestion. Pharmacokinetic parameters indicate
that it is eliminated with a half-life estimated of approxi-
mately 15h, thus supporting the once-daily dosing. Fi-
nally, the pharmacokinetics was linear in the dose range
of 750–1500 mg of GlcN.S, but not clearly defined at
higher doses [35].
Older techniques were not sensitive enough to moni-
tor GlcN plasma concentrations giving erratic values.
Previous human and animal studies failed to detect cir-
culating endogenous GlcN.S [35-37] or GlcN.H [38] at
concentrations ranging from as low as 10 to as high as
200 ng/ml. The potential pathophysiological significance
of this variability should be further investigated. Re-
peated once-daily doses of around 20 mg/kg GlcN.S
showed a similar pharmacokinetic profiles with a peak
plasma concentration (Cmax) around 10 μM, while the
GlcN concentration in synovial fluid was only 23.5%
lower than that in plasma [39,40]. Therefore, according
to published results, GlcN is well absorbed after re-
peated oral administration. Furthermore, taking into ac-
count other pharmacokinetic studies in humans, the
Cmax after a once daily dosing of 20 mg/kg GlcN.S is
about 10 μM [32].
The National Institutes of Health (NIH)-sponsored the
GlcN hydrochloride (GlcN.H)/Chondroitin sulfate Arth-
ritis Intervention Trial (GAIT), which was aimed at
studying the effect of these two compounds on pain and
function in knee OA patients. As part of this initiative,
pharmacokinetic studies were undertaken. GlcN concen-
trations found in this study were much lower than those
found in patients treated with GlcN.S 1500 mg. Thus,
after a single-dose of GlcN.H 500 mg, the mean plasma
Cmax was 3 μM in healthy volunteers. Moreover, the
Cmax and the area under the curve of GlcN were even
lower when the GlcN.H was given chronically in
fractioned doses of 500 mg three times daily reaching a
Cmax of 211 ng/mL [41]. The mean plasma Cmax was
achieved after a single dosage of 1500 mg GlcN.H, given
orally with 6 capsules of 250 mg each after a three-
month treatment. In addition, the bioavailability of GlcN
was decreased in patients who took the compound in
combination with chondroitin sulfate [41].
Therefore a topical and crucial question is whether 10
μM GlcN has biological effects in in vitro systems, animal
models, and in human subjects. Animal studies showing
significant effects of GlcN not only at cartilage level in OA
models but also in other systems were achieved at doses15- and 20-fold greater than typical doses consumed by
human subjects [42,43]. Most in vitro studies of GlcN.S
and GlcN.H activity on joint tissue and chondrocytes have
been performed in the 500 and 5000 μM range [32,44].
Some studies have also described some beneficial effects
of GlcN.S and GlcN.H at in vitro concentrations around
50 μM and even as low as 10 μM [23,32]. Nonetheless,
the majority of published papers report much higher GlcN
doses leading to high concentrations, far from those
achieved after the recommended dosing in human
OA treatment. For this reason, more studies are required
to assess the biological activity of 10 μM GlcN in order
to gain mechanistic insight of its actions on OA joint
tissues [43].
Finally several key questions remain unanswered. Is
ageing related to a decrease of endogenous GlcN synthe-
sis? Do changes in eating habits contribute to elevated
requirements of exogenous GlcN? Is endogenous GlcN
enough to supply chondrocyte metabolism? At the
present time these questions remain unanswered. These
points should be clarified in future studies to estimate
whether administering GlcN is pertinent and whether
GlcN provides beneficial effects on joint health.
How can GlcN contribute to cartilage maintenance in
healthy subjects and how can this be demonstrated?
There are currently no studies that have tested GlcN as
a chondroprotective agent in a preventive context.
Nevertheless, there is some indirect evidence from pub-
lished trials, showing a possible role of GlcN as a pre-
ventive agent in the progression of knee OA. GlcN.S
indeed prevented joint space narrowing (JSN) in two
randomised, placebo controlled, double blind trials of 3-
year duration in knee OA [1,2]. Several important points
can be gleaned from these trials. The first one is the
mild to moderate characteristics of the patient popula-
tion at baseline. The effects observed in this population
may therefore be extrapolated, with some caution, to the
general population at risk for OA. The second point is
that the subgroup analysis of postmenopausal female pa-
tients showed more effects on joint structure in this sub-
group than in the overall population [45]. Being a female
carries a greater risk factor for the development of OA
and the effects observed in this subgroup of patients
may be predictive of the response to treatment or of its
preventive effect if the treatment is initiated earlier. The
third point is that some effects have been observed on
the contralateral knee in these two long-term trials with
GlcN.S. The minimum joint space width (JSW) of the
contralateral knee was 4.72 ± 1.52 mm, which is similar
to the values observed in the general population. The ef-
fect of GlcN.S on the contralateral knee was not signifi-
cantly different from placebo, but there was a trend for
prevention of OA (p = 0.17). The fourth point is that the
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dent in these patients with better-preserved joint space
width at baseline, with joint structure closer to that of
the general population [46]. The fifth point is that the
patients in these two long-term studies were followed
for another 5 years after the termination of the 3-year
trials. Pooled incidence of total knee replacement during
a mean follow up was lower in GlcN.S-treated popula-
tion than in placebo group (14.5% vs. 6.3 %, p = 0.024)
[47]. However, one important limitation of this kind of
study is that in the follow up period the patients have
been treated in different ways. The debate about possible
clinical efficacy is based on two 3-year studies, but re-
cent analysis of 4 structure-modifying trials did not con-
firm the preventive effect of GlcN.S or GlcN.H [48].
Recently, the EFSA panel of experts has published its
scientific position in relation to the substantiation of a
health claim related to GlcN and maintenance of joints
[49]. The claimed effect was that GlcN “contributes to
the protection of joint cartilage exposed to excessive
motion or loading and helps to improve the range of
motion in joints”. The target population proposed by the
applicant was healthy individuals exposed to excessive
load on the joint. Maintenance of joints was a beneficial
physiological effect. The applicant provided two human
studies as pertinent to the claim. The first study was a
randomized, double-blind, placebo-controlled trial [50]
including 121 male patients who had a recent history of
acute knee sport injury. They received either 1.5 g GlcN
(n=62) per day or placebo (cellulose; n = 59) for 28
days. Pain and functional ability were evaluated at the
beginning of the study and at 7, 14, 21 and 28 days. Sup-
plementation with GlcN demonstrated significant im-
provement in knee flexion and extension but not in pain
and swelling. The EFSA panel of experts considered that
the provided evidence did not establish that patients
with acute knee injury are representative of the target
population with regards to the status of joint tissues or
that results obtained in studies on subjects with acute
knee injury can be extrapolated to the proposed target
population (healthy individuals exposed to excessive load
on the joints). In the second human study [51], 21 male
soccer players (19–22 years of age, mean 20.3) and as, a
control group, 10 male college students (20–27 years of
age, mean 23.5) were recruited. They carried out an
open label intervention with GlcN.H. To this end, the
subjects were divided into two groups that received 1.5 g
(n=9) or 3 g (n=10) GlcN per day for three months.
Urinary samples were taken at baseline, after the GlcN
administration (at three months) and three months after
withdrawal of GlcN administration (at six months). The
end point of the study involved measurement of the
urinary concentrations of CTX-II, C2C, two markers of
type II collagen degradation, CPII, a marker of type IIcollagen synthesis, and the ratio CTX-II/CPII. The ad-
ministration of 1.5 to 3 mg of GlcN significantly de-
creased CTX-II levels (p<0.01) [51] but the effect was
transient and disappeared after withdrawal of the admin-
istration. The panel has noted that this intervention
study was not adequately controlled for factors that may
have influenced the urinary analysis over the duration of
the study, and that the provided evidence did not estab-
lish that changes in urinary CTX-II over a period of
three months can predict significant changes in type II
collagen in joint cartilage. The panel concluded that a
cause and effect relationship has not been established
between the consumption of GlcN and the maintenance
of joint health because of missing appropriate clinical
trials in the target (i.e. healthy) population. Besides some
evidence for the beneficial effects of GlcN, the remarks
of the EFSA outline the limitations of clinical investiga-
tions to demonstrate maintenance of joint health.
Can GlcN reduce the risk of OA development?
The question as to whether GlcN has effectiveness to
prevent OA development has not been tested specifically
among human subjects. Therefore, it is necessary to
consider the processes by which OA develops, and make
extrapolations from observations made in animal models
and other types of studies about how GlcN might have
efficacy in this situation.
With respect to the potential of an intervention as a
preventive strategy for OA, it is important to realize that
such an effect could be mediated either through an in-
fluence on the risk factor profile, or through biological
mechanisms that interact directly with pathophysio-
logical processes in OA.
The effects of GlcN on other constitutional character-
istics that might represent risk factors for OA (such as
body weight) are unlikely or untested, with the possible
exception of systemic inflammation. Elevated C-reactive
protein levels have been associated with OA [52] and
with the progression of hand and wrist OA [53]. The
pathophysiological basis of this relationship is uncertain,
but it is possible that it reflects the effects of adipose-
mediated inflammation on articular structures, or, alter-
natively, some level of synovitis. In addition, studies dur-
ing the past 2 years have uncovered diverse pathways
that cause chondrocytes to become activated and pro-
duce pro-inflammatory mediators, through activation of
inflammatory genes regulated by transcription factors
such as NF-κB [54]. Furthermore, animal studies [55,56],
and one human clinical trial [57], have suggested that
the suppression of inflammation may reduce structural
progression of OA. It has been proposed that GlcN
might be able to intervene in these inflammatory path-
ways through a number of mechanisms. For example,
Imagawa et al. found that O-GlcNAc could prevent
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in the IL-1β promoter and this was associated with
decreased expression of IL-1β [58]. Other investigators
have generated in vitro evidence that GlcN.S attenu-
ates NF-κB activation at concentrations comparable to
those seen in patients following oral supplemental in-
gestion [59].
Due to the competition between GlcN and glucose not
only at the level of cellular uptake through the GLUT
transporters but also in the hexosamine pathway (one of
the alternative routes of glucose metabolism), patients
treated with this compound may have increased insulin
resistance, as suggested by findings in some animals
studies, although not in others [42,60,61]. It is therefore
important to address the question: “Could oral intake
of GlcN interfere with metabolic syndrome and insulin
resistance?” With respect to any influence on an individ-
ual’s risk factor profile, there is a potential for an adverse
interaction of GlcN with aspects of the metabolic
syndrome, which is common among elderly people
with OA [62]. Effects of GlcN on insulin sensitivity
through the hexosamine biosynthetic pathway have been
reported in animal models [63]. Indeed, intravenous
GlcN was used to produce an animal model for insulin
resistance and diabetes as part of early research in that
field. It is important to investigate the potential negative
side effects of GlcN on glucose metabolism, in particular
in diabetic and ‘pre-diabetic’ patients. Several studies
have tested this possibility. Studies from Scroggie et al.
[64] and Muniyappa et al. [65] showed no effect on insu-
lin resistance after GlcN use, whereas Pham et al. [66]
reported data indicating that GlcN worsens insulin sen-
sitivity at doses that are being taken for OA.
In one metabolic study of oral GlcN on serum glucose
and insulin levels among 16 patients with OA, three par-
ticipants demonstrated significant incremental elevations
in glucose levels after ingestion of GlcN.S [67]. The
authors concluded that GlcN ingestion might affect
glucose levels and consequent glucose uptake in patients
who have untreated diabetes or glucose intolerance.
Dostrovsky et al. recently performed a systematic review
to determine if exogenous GlcN adversely affects glucose
metabolism in humans [68]. They included 11 studies
(6 randomized controlled trials and 5 prospective stud-
ies). Four found decreased insulin sensitivity or in-
creased fasting glucose in subjects taking GlcN. They
concluded that the available evidence is mixed with re-
gard to the effect of oral GlcN on glucose metabolism,
and that more studies are needed, particularly some in-
cluding subjects at high risk for impairment in glucose
homeostasis.
In contrast, high intravenous and intra-arterial doses
of GlcN did not affect insulin sensitivity, secretion or ac-
tion [69,70]. Another study in healthy volunteers thatreceived orally repeated once-daily doses of 1500 mg
GlcN.S did not show any changes in serum insulin or
blood glucose levels [71]. In turn, patients with Type 2
diabetes receiving a combination of GlcN and chondro-
itin sulfate for 3 months had no change in their diabetes
management or hemoglobin A1c concentrations [64].
Finally, fasting plasma glucose levels were not modified
in short-term clinical trials with GlcN.S, as well as in
the Reginster long-term trial [1]. In contrast, Pavelka
reported that four patients developed diabetes during a
3-year study; however, three of them were in the placebo
group and only one was on GlcN.S treatment [2]. A sys-
tematic literature review suggests that GlcN has no ef-
fect on fasting blood glucose levels, glucose metabolism,
or insulin sensitivity at any oral dose level in healthy
subjects, individuals with diabetes, or those with im-
paired glucose tolerance [61]. As concluded in the latter
reference, the available evidence implicating GlcN as a
diabetogenic agent are limited to rodent infusion studies
and in vitro observations, experimental models that were
determined not to be relevant to humans. Longitudinal
studies in large cohorts of healthy human subjects are
therefore needed.
Some animal studies and human case reports suggest
that chronic use of GlcN in diabetic or “pre-diabetic” in-
dividuals might lead to or exacerbate insulin resistance.
However the level of proof is not sufficient and we lack
long-term studies of GlcN use in individuals with dia-
betes or pre-diabetes. Based on the available evidence,
no specific recommendation for controlling glycemia in
patients taking GlcN is proposed.
The existence of the conflicting published reports
highlights the paucity of information and the need for
further studies in this area.
Concluding remarks
GlcN is one of the most widely used “over the counter”
dietary supplements for the management of OA. In
some European countries GlcN is a registered drug. The
aim of the Hohenheim Conference and this consensus
paper was not to explore one more time the efficacy of
GlcN on symptoms and structure in patients with knee
or hip OA. This has already been done numerous times
in meta-analyses and literature reviews, including a
Cochrane review [72,73]. Despite the extensive studies
and interest in this compound, its use is still a matter
for debate. The aim of this conference was to provide
consensual comments on the potential beneficial effect
of GlcN on joint health (Tables 1 and 2).
The first question to address was whether normal
chondrocytes need GlcN for their physiological function
and metabolism. The answer is clearly no because cells
favour glucose as the main fuel for energetic production
and production of cartilage proteoglycans [24]. In
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GlcN is completely inhibited [74]. Substrate level com-
petition may operate in situations where there is a local
decrease in glucose levels or a significant increase in the
local concentration of GlcN (millimolar concentrations).
Another aspect of the question concerns GlcN and age-
ing chondrocytes. During the process of chondrocyte
senescence, several factors (cell apoptosis, oxidative
stress, decreased responsiveness to growth factors, telo-
mere erosion, glycation of ECM macromolecules) con-
tribute to the modification of ECM production in a
quantitative and qualitative manner and, as a conse-
quence, this may lead to decreased capacity of the cartil-
age repair. The lesions observed in ageing cartilage seem
similar to those observed in OA cartilage. Thus cartilage
ageing is a major risk factor of OA but for many scien-
tists it is still considered to be a different condition to
OA. It is therefore important to develop novel tools and
assays for mechanistic in vitro studies on the effect of
GlcN on cartilage ageing. It will be also interesting to
see whether GlcN can influence the production of ad-
vance glycation end products (AGEs).
The local anti-inflammatory action of GlcN has
clearly been demonstrated by many in vitro studies
[44,58,75-78]. An important consideration of future re-
searches could be more in-depth studies of the systemic
and general anti-inflammatory effects of GlcN. This will
be interesting in the context of a link between metabolic
syndrome and knee OA; it will be indeed important to
explore whether GlcN might be able to interfere with
metabolic syndrome. One proposal could be to observe
the systemic effect of GlcN, for instance on ultrasensitive
CRP, a marker of molecular inflammation associated
with metabolic syndrome. Improving this molecular in-
flammatory state in patients with knee OA and meta-
bolic syndrome could be an important target of future
studies. This potential general effect of GlcN surely
needs to be better explored. A recent study showed that
high intake of GlcN in rabbits with both articular and
vascular disease, is able to diminish the general inflam-
mation and reduce atheromatous plaques, suggesting
that oral GlcN.S may exert systemic anti-inflammatory
actions [42].
In the line of a potential systemic effect of GlcN, data
regarding the extra articular actions of GlcN, especially
on muscle are missing. A recent work shows that in pa-
tients suffering from knee OA, GlcN.S reduced pain and
improved muscle strength with resistance training in a
randomized placebo controlled trial [79]. GlcN.S might
also act at distance of the joint, in tissues where its con-
centration is high such as intestine and liver [38]. This
might represent an interesting approach in the future.
How and to whom should we propose any preventive
effect of GlcN? Our proposal is to stratify and selectsome populations without symptomatic OA but submit-
ted to a risk factor, which could potentially be influenced
by GlcN. Thus, individuals with a history of traumatic
joint injuries (i.e. meniscal tears, anterior cruciate liga-
ment injury) or subjects engaged in high load ballistic
sports with repetitive joint impact presenting a higher
risk of cartilage degradation may be targeted. In this set-
ting, GlcN may present a beneficial effect on joint struc-
ture since we hypothesize that oral GlcN is locally
available into the joint and may favour cartilage repair.
Similarly, individuals with early OA (doubtful stage 1 in
the Kellgren-Lawrence classification system) could be a
target for preventive treatment with GlcN. Ageing
people without overt OA is also a potentially good popu-
lation to target. Finally, individuals with metabolic syn-
drome constitute an interesting population to follow,
since GlcN may demonstrate not only local but also sys-
temic effects. One key (but difficult) question is to deter-
mine which surrogate biomarkers should be adopted to
demonstrate the clinical benefits of GlcN on OA devel-
opment. In other words, how can we detect small varia-
tions in cartilage metabolism that could potentially
indicate increased cartilage turnover in normal subjects?
So far no such biomarkers have been validated in normal
subjects. Assays for several biological molecules have
been developed as indicators of cartilage and bone me-
tabolism in OA patients [80]. A recent study comparing
soccer players (without knee pain and without radio-
logical OA) to healthy but non-sporty young subjects,
has shown that treatment with GlcN for 3 months de-
creases type II collagen degradation (as measured by
urinary CTX-II levels) but GlcN did not affect the in-
crease of type II collagen synthesis (reflected by CP-II
serum level) [51]. We propose that a combination of
biological markers such as Coll2-1, Coll2-1 NO2, COMP,
HA or fibuline-3 fragments (Fib3-1 and Fib3-2) should
be used as surrogate biomarkers of cartilage function in
such studies [4,81]. In addition, sophisticated and new
imaging modalities such as MRI with dGemric (delayed
gadolinium-enhanced MRI) would be interesting to use
in this context for examining the content of biological
markers associated with load-bearing (i.e. proteoglycans
and their constituent GAGs) in cartilage. The volume of
cartilage, the presence and severity of synovitis and/or
bone marrow lesions (BML) could also be investigated
by MRI. In a recent and relevant study performed in
obese patients without symptomatic knee OA (only 32%
present radiographic knee OA), it was demonstrated that
weight loss has structure modifying effects as expressed
by a gain in the medial dGemric index which indirectly
reflects the GAG content of cartilage [82]. This kind of
study using a surrogate marker such as dGemric index is
typically one that could be applied for studying the
structure modifying properties of GlcN in patients
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factors for developing OA. The use of scintigraphy with
specific binding of macrophages may also be interesting
in future studies on GlcN [83]. The goal of this kind of
study should be to demonstrate that long-term treat-
ment with GlcN may favourably influence some
markers of cartilage metabolism, a prerequisite condi-
tion that would be indicative but not conclusive of a
chondroprotective effect.
The final question concerns the type of GlcN and the
dosage of the molecule that should be recommended.
GlcN salts are hydrolysed by the acidic pH of the gastric
cavity and therefore it is probable that both GlcN.H and
GlcN.S result in the same form preceding subsequent
intestinal absorption and liver metabolism. A recent
paper showed bioequivalence of the two forms. Both in
rats and in human volunteers, a single dose charge of
GlcN.OH or GlcN.S results in the same levels of GlcN
excretion in the urine [84]. Therefore, there is not suffi-
cient data to differentiate between the two forms of
GlcN,
at least from a pharmacokinetic point of view. Absorp-
tion of GlcN after oral administration is limited, leading
to low bioavailability (varying between animal species
and human).
GlcN remains a controversial molecule; general conclu-
sions and perspectives are to move toward new types of
clinical trials in healthy subjects that may be able to explore
the potential role of GlcN, considered as a nutriment, to
prevent the secondary development of osteoarticular dis-
eases. We have proposed in the present paper some state-
ments and proposals for further studies.Abbreviations
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